Viatris, Inc. (VTRS)
NASDAQ:VTRS
VTRS Stock Chart & Stats
$13.37
>-$0.01(-0.04%)
At close: 4:00 PM EST
$13.37
>-$0.01(-0.04%)
Day’s Range― - ―
52-Week Range$6.85 - $16.47
Previous CloseN/A
Volume2.11M
Average Volume (3M)11.22M
Market Cap
$15.39B
Enterprise Value$28.75B
Total Cash (Recent Filing)$1.45B
Total Debt (Recent Filing)$14.70B
Price to Earnings (P/E)―
Beta0.93
Next Earnings
May 11, 2026EPS Estimate
0.5Next Dividend Ex-DateN/A
Dividend Yield3.99%
Share Statistics
EPS (TTM)0.57
Shares Outstanding1,151,393,000
10 Day Avg. Volume11,378,506
30 Day Avg. Volume11,220,858
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.99
Price to Sales (P/S)1.02
P/FCF Ratio7.52
Enterprise Value/Market Cap1.87
Enterprise Value/Revenue2.01
Enterprise Value/Gross Profit5.74
Enterprise Value/Ebitda-72.72
Forecast
1Y Price Target
$15.25Price Target Upside14.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)2.45
Revenue Forecast (FY)$14.62B
Bulls Say, Bears Say
Bulls Say
Capital Allocation And Business DevelopmentA more aggressive business development approach combined with shareholder-friendly capital allocation, including targeted acquisitions and share repurchases funded by free cash flow, could boost revenue growth and returns.
New Product CommercializationA promising fast-acting pain treatment with positive regulatory interactions and a focused outpatient launch strategy could drive meaningful new revenue, particularly if partnership deals accelerate market reach.
Strategic GuidanceManagement's clear long-term growth targets and structured framework could strengthen investor confidence and support valuation upside as execution advances.
Bears Say
Execution RiskSignificant execution risk across commercial operations and clinical development means key late-stage catalysts could materially weaken the company's outlook if milestones are missed.
Market Sentiment And ValuationShare price may be vulnerable to an overbought reaction driven mainly by expectations of cost reductions rather than sustained operational improvement, creating downside risk if savings prove insufficient.
Viatris News
VTRS FAQ
What was Viatris, Inc.’s price range in the past 12 months?
Viatris, Inc. lowest stock price was $6.85 and its highest was $16.47 in the past 12 months.
What is Viatris, Inc.’s market cap?
Viatris, Inc.’s market cap is $15.39B.
When is Viatris, Inc.’s upcoming earnings report date?
Viatris, Inc.’s upcoming earnings report date is May 11, 2026 which is in 45 days.
How were Viatris, Inc.’s earnings last quarter?
Viatris, Inc. released its earnings results on Feb 26, 2026. The company reported $0.57 earnings per share for the quarter, beating the consensus estimate of $0.532 by $0.038.
Is Viatris, Inc. overvalued?
According to Wall Street analysts Viatris, Inc.’s price is currently Undervalued.
Does Viatris, Inc. pay dividends?
Viatris, Inc. pays a Quarterly dividend of $0.12 which represents an annual dividend yield of 3.99%. See more information on Viatris, Inc. dividends here
What is Viatris, Inc.’s EPS estimate?
Viatris, Inc.’s EPS estimate is 0.5.
How many shares outstanding does Viatris, Inc. have?
Viatris, Inc. has 1,151,393,000 shares outstanding.
What happened to Viatris, Inc.’s price movement after its last earnings report?
Viatris, Inc. reported an EPS of $0.57 in its last earnings report, beating expectations of $0.532. Following the earnings report the stock price went down -5.162%.
Which hedge fund is a major shareholder of Viatris, Inc.?
Currently, no hedge funds are holding shares in VTRS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Viatris Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.25 (14.06% Upside)
$15.25 (14.06% Upside)
Blogger Sentiment
Neutral
VTRS Sentiment 50%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 10.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $137.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
56.19%
12-Months-Change
Fundamentals
Return on Equity
-22.99%
Trailing 12-Months
Asset Growth
-10.38%
Trailing 12-Months
Company Description
Viatris, Inc.
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
VTRS Company Deck
VTRS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized solid 2025 execution (revenue up ~2% operationally, adjusted EBITDA $4.2B), robust cash generation and a strengthened R&D pipeline with multiple regulatory milestones and late-stage programs. Management completed an enterprise strategic review targeting $650M gross savings ($400M net) with phased implementation and reinvestment to support growth. Near-term headwinds include an India facility shutdown (temporary), modest 2026 guidance (~2% revenue/EBITDA growth), margin pressure from LOEs and lower-margin mix, and one-time restructuring/transaction costs (~$700M range). Overall, the company presents a constructive, forward-looking plan with credible cash and pipeline catalysts, while acknowledging short-term execution and timing risks.View all VTRS earnings summariesVTRS Net sales Breakdown
64.45% Brands
35.55% Generics
VTRS Stock 12 Month Forecast
Average Price Target
$15.25
▲(14.06% Upside)
Technical Analysis
Dr Reddy's Laboratories
―
Perrigo Company
―
Teva Pharmaceutical
―
ANI Pharmaceuticals
―
Amneal Pharmaceuticals
―
Ownership Overview
0.28% Insiders
27.06% Mutual Funds
21.08% Other Institutional Investors
23.64% Public Companies and Individual Investors